国产一区二区免费,翔田千里AV,无码电影,红杏亚洲影院一区二区三区,国产精品欧美激情

更新于 5月27日

(Senior) Scientist, DMPK(ADME) (MJ018530)

1.4-2.4萬(wàn)
  • 北京昌平區(qū)
  • 經(jīng)驗(yàn)不限
  • 碩士
  • 全職
  • 招1人

職位描述

生物藥藥物分析
體外ADME科研員(北京) 崗位描述: 百濟(jì)神州DMPK部門正在尋找一名有才華和上進(jìn)心的科研員加入團(tuán)隊(duì),該人選將專注于進(jìn)行體外吸收、分布、代謝和排泄(ADME)研究,并與快節(jié)奏的藥物研究團(tuán)隊(duì)合作,圍繞小分子的體外ADME特征提供科學(xué)的方向。 工作職責(zé):
  • 與早研同事合作,評(píng)估化合物ADME性質(zhì),以支持藥物設(shè)計(jì)和構(gòu)效關(guān)系(SAR)的藥物化學(xué)研究。
  • 獨(dú)立開展,分析和解釋體外ADME實(shí)驗(yàn),包括但不限于代謝穩(wěn)定性,滲透性,蛋白結(jié)合率,酶誘導(dǎo)/抑制,轉(zhuǎn)運(yùn)體和藥物相互作用評(píng)估。
  • 獨(dú)立開發(fā)LC-MS/MS方法并處理體外樣品。
  • 獨(dú)立操作、故障排除和維護(hù)LC-MS/MS設(shè)備。
  • 在藥物研究中圍繞體外ADME策略,同時(shí)探索新的技術(shù)和方法。
任職要求:
  • 藥代動(dòng)力學(xué)、藥物代謝、藥學(xué)等相關(guān)專業(yè)碩士及以上學(xué)位
  • 在體外ADME方面具有豐富的實(shí)踐經(jīng)驗(yàn)
  • 具有對(duì)細(xì)節(jié)的敏銳眼光和專注于明確研究結(jié)果的能力
  • 良好的人際關(guān)系,溝通,解決問題和協(xié)作能力,在快節(jié)奏的環(huán)境中提供高質(zhì)量的結(jié)果
百濟(jì)神州全球勝任力 當(dāng)我們通過以下十二項(xiàng)全球勝任力,展現(xiàn)出 "患者為先"、"無界協(xié)作"、"銳意創(chuàng)新 "和 "追求卓越 "的價(jià)值觀時(shí),我們就能幫助全世界更多患者獲得更多負(fù)擔(dān)得起的藥品。 ●團(tuán)隊(duì)協(xié)作 ●提供并征求坦誠(chéng)及可行的反饋 ●自我認(rèn)知 ●兼容并蓄 ●積極主動(dòng) ●開拓精神 ●持續(xù)學(xué)習(xí) ●擁抱變化 ●結(jié)果導(dǎo)向 ●分析性思維/數(shù)據(jù)分析 ●卓越財(cái)務(wù) ●清晰溝通 BeiGene Global Competencies When we exhibit our values of Patients First, Collaborative Spirit, Bold Ingenuity and Driving Excellence, through our twelve global competencies below, we help get more affordable medicines to more patients around the world. ●Fosters Teamwork ●Provides and Solicits Honest and Actionable Feedback ●Self-Awareness ●Acts Inclusively ●Demonstrates Initiative ●Entrepreneurial Mindset ●Continuous Learning ●Embraces Change ●Results-Oriented ●Analytical Thinking/Data Analysis ●Financial Excellence ●Communicates with Clarity 求職者隱私申明: 百濟(jì)神州致力于尊重和保護(hù)您的個(gè)人信息權(quán)利,并承諾依據(jù)合法、正當(dāng)、必要和誠(chéng)信的原則處理您的個(gè)人信息(包括個(gè)人敏感信息 )。 由于百濟(jì)神州在全球范圍內(nèi)開展業(yè)務(wù),我們可能需要基于人力資源管理等合理業(yè)務(wù)目的而將您的個(gè)人信息發(fā)送和/或存儲(chǔ)在位于您所在國(guó)家以外其他國(guó)家(例如:美國(guó))的服務(wù)器和數(shù)據(jù)庫(kù)中,詳情參見百濟(jì)神州《求職者隱私政策》(百濟(jì)神州官網(wǎng) - 隱私政策 - 求職者隱私政策)。 如您主動(dòng)向我們提供您的簡(jiǎn)歷信息或其他個(gè)人信息,則視為您已經(jīng)充分理解并確認(rèn)接受百濟(jì)神州《求職者隱私政策》內(nèi)容。如您對(duì)此有任何疑問的,請(qǐng)勿提交簡(jiǎn)歷信息或其他個(gè)人信息。 BeiGene is committed to respect and protect your personal information rights, and will process your personal information, including your sensitive personal information, based on the principles of legality, legitimacy, necessity, and integrity. Due to the reasonable business need for human resource management as a result of BeiGene’s global operation, your personal information may be transferred and/ or stored in a server/database located in a third country (e.g., the United States) other than your own country. For further details, please refer to BeiGene Job Applicant Privacy Policy (BeiGene official website - Privacy Policy - Job Applicant Privacy Policy). If you voluntarily provide your resume or other personal information to us, it is deemed as you have thoroughly acknowledged and accepted BeiGene Job Applicant Privacy Policy. If you have any concern, please DO NOT submit your resume or any other personal information.

工作地點(diǎn)

北京市昌平區(qū)科學(xué)園路30號(hào)

職位發(fā)布者

張婧媛/百濟(jì)神州研發(fā)招聘recruiter

立即溝通
公司Logo百濟(jì)神州北京
About BeiGene BeiGene is a publically traded(BGNE, NASDAQ), globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. Our cancer biology platform addresses the importance of tumor-immune system interactions and the value of primary tumor biopsies in developing new cancer models. We have a global team of over 200 individuals, including over 150 scientists and clinicians, and a world-renowned scientific advisory board, with deep scientific talent, extensive pharmaceutical experience, and a commitment to improving the lives of cancer patients around the world. Our clinical pipeline is comprised of novel oral small molecules and monoclonal antibodies(mAb) for cancer, including an anti-PD-1 monoclonal antibody, a best-in-class BTK inhibitor, a RAF dimer inhibitor, a best-in-class PARP inhibitor, and a variety of combination clinical studies. In addition, our robust preclinical programs are expected to generate more small molecule and mAb drugs for clinical development in coming years. For more information, please visit our website at www.beigene.com.
公司主頁(yè)
免费的av| 中文字幕在线中文字幕一区WWW| 欧美 中文 人妻| 亚州色小说| 一本久久a久久免费精品顶级| 国产人人操| 青青草视频网| 98在线视频噜噜噜国产| 少妇愉情理伦片丰满丰满午夜| 日本高清色一区Aⅴ| 国产精品49P| 日本潮喷在线播放| 国产成人精品视频一区二区不卡| 日韩一区自拍| 华安县| 日韩欧美高清一区二区三区| 新天堂√中文在线| www.香蕉| 久久网址| 中文字幕日韩人妻不卡一区二区| 国产一区二区三区欧美亚洲| 人妻 视频一区| 国产精品swag一区二区入口| 天天日天天爱| 国产xxx| 色噜噜视频| 久久精品亚洲国产AV| 无码gif| 亚洲AV无码一区二区三区网址| 色涩av| 日本国产欧美在线| 国产熟女91| mk7.CC| 91干b| 无码精品国产D在线观看| 精品九九九九九九换人妻| 91中文字幕在线观看| 亚洲欧美日韩天堂三区| 4hu 亚洲精品| 99精品欧美一区二区蜜桃免费| 欧美人与动牲交a精品|